Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

Name: Gene name corresponding to the UniProt ID
UniProt ID: UniProt accession number
Publication: Study Reference
Condition: e.g.ALS – Control, ALS Fast – ALS Slow
Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
Regulation: Direction of change (upregulated or downregulated)
Cohorts: Cohort size used for each study
Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au

Biomarker Name

UniProt ID

Condition

Publication

Sample Type

Sort by:

Ascending Descending

Total Records Found: 2896, showing 100 per page
Biomarker Name	UniProt ID	Publication	Condition	Sample Type	Regulation	Cohorts	Average age at onset	Average age at collection	Average PMI
AGT	P01019	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
AGT	P01019	Zhou et al. 2023	SO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
AGT	P01019	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
AGRN	O00468	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
AGRN	O00468	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
AGAP3	Q96P47	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
AGAP2	Q99490	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
AFM	P43652	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
AFM	P43652	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
AFG3L2	Q9Y4W6	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
AFF4	Q9UHB7	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
AEBP1	Q8IUX7	Andrés-Benito et al. 2020	ALS – Control	CSF	Up	15 ALS, 15 control		61 ± 10.8
ADSS2	P30520	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ADH5	P11766	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
ADH5	P11766	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ADD2	P35612	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ADD1	P35611	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ADAMTSL4	Q6UY14	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
ADAMTS4	O75173	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ADAMTS16	Q8TE57	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ADAMTS1	Q9UHI8	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ADAM17	P78536	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ADAM15	Q13444	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ADAM10	O14672	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
ACY3	Q96HD9	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
ACTR3B	Q9P1U1	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
ACTR3	P61158	Zubiri et al. 2018	Late ALS – Early ALS (ALS slow cohort)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
ACTR2	P61160	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACTR10	Q9NZ32	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
ACTN4	O43707	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACTN2	P35609	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACTN1	P12814	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACTN1	P12814	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
ACTN1	P12814	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
ACTG2	P63267	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACTG1	P63261	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ACTG1	P63261	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
ACTG1	P63261	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
ACTBL2	Q562R1	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACTB	P60709	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACTB	P60709	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
ACTB	P60709	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
ACTB	P60709	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
ACTA1	P68133	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ACSL6	Q9UKU0	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
ACPL2	Q8TE99	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
ACP1	P24666	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
ACOT7	O00154	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
ACOT7	O00154	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACOT7	O00154	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
ACO2	Q99798	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACO1	P21399	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACO1	P21399	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
ACLY	P53396	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACIN1	Q9UKV3	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
ACE	P12821	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ACAT2	Q9BWD1	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACAT1	P24752	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ACAN	P16112	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ACAD8	Q9UKU7	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
ABLIM2	Q6H8Q1	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
ABI3BP	Q7Z7G0	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ABHD14B	Q96IU4	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ABHD14B	B4DQI4	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
ABHD14A	Q9BUJ0	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
AATM	P00505	Oh et al. 2023	ALS – Control	CSF	Up	20 ALS, 20 control		59
AASDHPPT	Q9NRN7	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
AARS1	P49588	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
AARS	P49588	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
AACT	P01011	Oh et al. 2023	ALS – Control	CSF	Up	20 ALS, 20 control		59
AAAS	Q9NRG9	Andrés-Benito et al. 2020	ALS – Control	CSF	Up	15 ALS, 15 control		61 ± 10.8
A4	P05067	Oh et al. 2023	ALS – Control	CSF	Down	20 ALS, 20 control		59
A2M	P01023	Berrone et al. 2023	fALS – Control	Plasma	Down	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
A2M	P01023	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
A2M	P01023	Zubiri et al. 2018	Late ALS – Early ALS (ALS fast cohort)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
A1BG	P04217	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
A1BG	P04217	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
A1BG	P04217	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	Q5HY54	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	F5GY80	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WYC5	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	E9PMB9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A6XND1	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WXL8	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WTM7	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WW96	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WZW8	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WZ15	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087X1V9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A0A0MS87	Andrés-Benito et al. 2020	ALS – Control	CSF	Up	15 ALS, 15 control		61 ± 10.8
	E2QRM6	Leoni et al. 2019	BO-ALS – LO-ALS	PBMCs	Up	12 BO-ALS, 12 LO-ALS	(39-76) (BO-ALS), (33-81) (LO-ALS)
	A0A087WZH7	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WUK0	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WU91	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	A0A087WYJ9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
	E7EPU2	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)